Kornimate/medical-research-clean huggingface dataset:
the turkish version of the wuspi

Conditions: Shoulder Pain

Summary: wheelchair users frequently experience shoulder pain. it has been determined that in our country, the subjective assessment methods that will help to determine and monitor shoulder pain severity of wheelchair users are limited. the purpose of this study is to adapt the original english version of the wheelchair users shoulder pain index into turkish and to assess its validity and reliability. firstly, the original english version of wuspi was translated into turkish and culturally adapted, then applied to 100 wheelchair users to investigate the validity of the scale. the reliability of the scale was assessed by internal consistency and test-retest analysis and found a high internal consistency. validation of wuspi-tr was assessed by the concurrent validity method. to establish concurrent validity, wuspi scores were compared to spadi and ases scores by spearman correlation analysis. there was a positively excellent correlation with spadi and, negatively excellent correlation with ases. as a result, it is determined tath the turkish version of wuspi-tr is a valid and reliable tool.

the original version of wuspi was translated into turkish via multistep translation rules. it is culturally adapted into turkish. the semantic equivalence of the new scale was evaluated and the turkish version of the wuspi (wuspi-tr) has been created. it is applied to 100 wheelchair users to investigate the validity of the scale. people who are at least for 1 year using a manual wheelchair as their primary means of mobility, cognitively unimpaired, literate, and older than 18 years are included in this study. the reliability of the scale was assessed by internal consistency and test-retest analysis. as a result of the analysis, the cronbach alfa value was calculated as 0.894, and wuspi-tr was found to have high internal consistency. the wuspi-tr questionnaire was re-administered to 50 participants for 7 to 14 days for the test-retest method and the results were compared with the interclass correlation coefficient (icc) method. wuspi has been found to have high reliability (0.997). validation of wuspi-tr was assessed by the concurrent validity method. to establish concurrent validity, wuspi scores were compared to spadi and ases scores by spearman correlation analysis. the correlation coefficient of wuspi-tr with spadi is 0.931 and with ases was -0.812. these results show that there was a positively excellent correlation with spadi and, negatively excellent correlation with ases (p \< 0,001). as a result, the turkish version of wuspi-tr is a valid and reliable tool.

Eligibility criteria:
inclusion criteria: * accepting the participation * using manual wheelchairs as the primary mobility tool for more than a year exclusion criteria: * being illiterate, * having cognitive impairment

Keywords: wheelchair user wuspi turkish version validity and reliability
diagnostic utility of attention deficit hyperactivity disorder (adhd) by brain activity flow patterns analysis using evoked response potentials

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this research study is to study a device called an electroencephalograph (eeg) in the diagnosis of treatment of attention deficit hyperactivity disorder (adhd) in adults. people with adhd have symptoms such as difficulty sustaining attention, organizing, and managing impulsivity. they can have trouble in school, at work, and at home. subjects with adhd who participate in this study will be given a once daily stimulant medication called osmotic release methylphenidate (concerta) for 6 weeks, and have eeg testing done before and after the treatment period. subjects will perform a computer based cognitive task during eeg testing. the u.s. food and drug administration has approved osmotic release methylphenidate (concerta) for the treatment of adhd in adults and children. similar procedures, without medication, will be performed with a sample of healthy adults without adhd.


Eligibility criteria:
adhd subjects inclusion criteria: * male and female outpatients, aged 18-55 years * subjects meeting full criteria for the diagnosis of dsm-iv (diagnostic and statistical manual, version 4) attention deficit hyperactivity disorder (adhd) * absence of pharmacological treatment for adhd for at least one week. * right handedness exclusion criteria: * any other current psychiatric or medical condition determined to be clinically significant. * current use of psychotropics or any medication with clinically significant cns (central nervous system) effects. * mental retardation (iq \< 80). * significant sensory deficits such as deafness or blindness. * individuals with a history of substance dependence or abuse within the past 6 months. * pregnant or nursing females. * subjects with pre-existing structural cardiac abnormalities. * clinically significant abnormal laboratory values, electrocardiogram or blood pressure reading healthy control subjects inclusion criteria: * males and females, aged 18-55 years * subjects who do not meet full criteria for the diagnosis of dsm-iv attention deficit hyperactivity disorder (adhd), as determined by clinical evaluation and/or adhd module of structured diagnostic interview, completed by the study clinician. * right handedness exclusion criteria: * any current psychiatric or medical condition determined to be clinically significant. * current use of psychotropics or any medication with clinically significant cns effects. * mental retardation (iq \< 80). * significant sensory deficits such as deafness or blindness.

Keywords: adhd adults electroencephalography (eeg) concerta
genomewide screening of pathological myopia

Conditions: Pathological Myopia

Summary: the purpose of this study is to evaluate the possible candidate gene of pathological myopia

high myopia (pathological myopia) is caused by excessive axial elongation that primarily involves the ora-equatorial area and the posterior pole. peripheral fundus changes and posterior staphyloma formation are ophthalmoscopic evidences of this process. pathological myopia often accompanied by glaucoma, cataracts, macular degeneration, and retinal detachment, leading to blindness when the damage to the retina is extremely severe. population and family studies in chinese have provided evidence for a genetic component to pathologic myopia. children of myopic parents are more likely to have myopia than are children of nonmyopic parents. the ocular components (axial length, anterior chamber depth, and corneal curvature) and refractive errors of mz twins are more closely aligned than are those of dz twins. therefore, it is possible to search a potential candidate gene for myopia through the genomic study of pathological myopia.

Eligibility criteria:
inclusion criteria: * they are unrelated chinese subjects with high myopia ≦-6.00d. the diagnosis of myopia is determined by the refractive error. anisometropic individuals, with a refractive error of ≦-6.00 d for one eye and ≦-6.00 d for the other eye, with at least a 2-d difference between the two eyes, are considered unaffected. exclusion criteria: * individuals are excluded if there is known ocular disease or insult that could predispose to myopia, such as retinopathy of prematurity or early-age media opacification, or if they had a known genetic disease associated with myopia, such as stickler or marfan syndrome.

Keywords: pathological myopia, genomic
study of the effects of temperature on metabolism in human muscle

Conditions: Healthy

Summary: this study will examine the role of temperature in changing energy metabolism in human muscle. in order to do this, researchers will use magnetic resonance imaging (mri) to provide information about how parts of muscle operate during exercise. magnetic resonance imaging (mri) is a diagnostic tool that creates high quality images of the human body without the use of x-ray (radiation). in this study, mri will be used to measure the temperature and energy level of specific muscles during rest and exercise. in addition, the muscles being tested will be heated and cooled to see if temperature directly affects levels of energy in muscle.

this study will examine the role of temperature in modulating aspects of energy metabolism in human skeletal muscle. tests will be conducted at rest and during concentric dorsiflexion exercise of the tibialis anterior (ta) muscle using an existing custom-designed dynamometer in conjunction with mild local heating and cooling. magnetic resonance spectroscopy (mrs), performed in a 4-tesla whole-body nmr system, will be used to non-invasively measure muscle temperature and energy-state. specifically these tests will assess the extent to which temperature changes occur during aerobic exercise and how small temperature changes affect mitochondrial function in-vivo.

Eligibility criteria:
ages 18 to 50. male and female subjects. capable of giving informed consent. healthy normal volunteers. no cardiac pacemaker of implantable defibrillator. no aneurysm clip. no neural stimulator (e.g. tens-unit). no ear implant of any type. no metal in the eye (e.g. from machining). no implanted device (e.g. insulin pump, drug infusion device). no metallic foreign body, shrapnel, or bullet.

Keywords: exercise mri mrs normal volunteer tibialix anterior
a clinical effectiveness study examining the efficacy and safety of ons-5010 in subjects with neovascular age-related macular degeneration (amd)

Conditions: Age-related Macular Degeneration; Neovascular Age-related Macular Degeneration; Wet Macular Degeneration

Summary: this research study will examine the safety and effectiveness of ons-5010 in participants with amd. the goal is to prevent vision loss by evaluating the effectiveness of ons-5010 as compared with ranibizumab.


Eligibility criteria:
inclusion criteria: * active primary subfoveal choroidal neovascularization lesions secondary to age-related macular degeneration (amd) in the study eye * best corrected visual acuity of 25-67 letters read (20/50 to 20/320 snellen equivalent) * study eye must: * have active leakage on fluorescein angiogram involving the fovea * have edema involving the fovea * be free of scarring, fibrosis, or atrophy involving the central foveal zone exclusion criteria: * previous subfoveal focal laser photocoagulation in the study eye * laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1-month preceding randomization * any concurrent intraocular condition in the study eye that may require medical or surgical intervention or contribute to vision loss within 1 year * active intraocular inflammation (grade trace or above) in the study eye * current vitreous haemorrhage in the study eye * polypoidal choroidal vasculopathy (pcv) in the study eye * history of idiopathic or autoimmune-associated uveitis in either eye * infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye * uncontrolled glaucoma in the study eye (defined as intraocular pressure ≥30 mmhg despite treatment with anti-glaucoma medication) * premenopausal women not using adequate contraception * current treatment for active systemic infection * known allergy to any component of the study drug or history of allergy to fluorescein , not amenable to treatment

Keywords: subfoveal choroidal neovascularization
itraconazole to prevent recurrent barrett's esophagus

Conditions: Barrett Oesophagitis With Dysplasia

Summary: recurrent barrett's esophagus (be) that occurs at the rate of 12.4%/year is the achilles heel of the endoscopic treatment of high-risk be. over time, after eradication, be ultimately recurs in as many as 30-50% of the patients putting them at risk for esophageal adenocarcinoma (eac), thereby undoing the benefits of an effective initial therapy. also, recurrences need retreatments that increase costs and complications including strictures and refractory ulcerations. a therapy to prevent recurrent be does not currently exist. itraconazole with its ability to inhibit important molecular pathways related to be development could enhance the long-term effectiveness of endoscopic eradication of high-risk be, thereby promoting a long-term cure


Eligibility criteria:
inclusion criteria: * patients with barrett's esophagus with either confirmed low-grade dysplasia or high grade dysplasia or intramucosal/t1 adenocarcinoma (see histologic review) being considered for endoscopic treatment. patients must have an eastern cooperative oncology group (ecog) performance status of 0-2 exclusion criteria: * inability to provide informed consent, new york heart association class iii or iv congestive heart failure (chf), liver function tests (lft)\>3x upper limit of normal, drug allergy to itraconazole, pregnancy, prolonged qtc (\>450 ms for men and qtc\>470 ms for women) or critical drug interactions with other medications metabolized by cytochrome p450(cyp)3a4.

Keywords: barrett's esophagus
does obesity increase the risk of conversion and short term complications in laparoscopic rectal surgery?

Conditions: Rectal Cancer; Obesity

Summary: obesity is on the rise in the western population and bmi has been shown to be associated with an increased risk of per- and postoperative complications. the investigators intend to study a population of more than 300 patients undergoing laparoscopic surgery for rectal cancer. the investigators main outcome measure will be the conversion rate, and the investigators also intend to study other indications of short term complications, such as peroperative bleeding, infection, re-operation and mortality. the investigators hypothesise that increased bmi does not increase the risk of conversion.


Eligibility criteria:
inclusion criteria: * patients with rectal cancer undergoing laparoscopic surgery, hvidovre hospital, denmark. exclusion criteria: * no exclusion criteria
comparing the efficacy of two neurofeedback protocols for generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: generalized anxiety disorder (gad) is one of the most prevalent mental disorders in adults, marked by excessive and uncontrollable worry about various events or activities. it is accompanied by symptoms such as restlessness, irritability, fatigue, difficulty concentrating, problems with sleep, and somatic symptoms. in addition, a critical and up-to-date comparison of different treatments for gad is crucial due to their high costs and unsatisfactory outcomes. eeg neurofeedback training has not reached the same level of evidence as more extensively validated non-pharmacological treatments, such as cognitive behavioral therapy.this study aimed to compare the efficacy of two protocols: one targeting alpha-theta amplitude increase and the other concentrating on smr.


Eligibility criteria:
inclusion criteria: * normal hearing and vision, * had never undergone neurofeedback sessions, * diagnosed as gad by a psychiatrist, * no history of neurological disorders * undergoing other therapies exclusion criteria: * started other treatments during the study * missed more than one session
safety and effectiveness of jetstream atherectomy system (j-supreme)

Conditions: Peripheral Arterial Disease

Summary: the purpose of this study is to evaluate the safety and effectiveness of the jetstream atherectomy system for the treatment of japanese patients with symptomatic occlusive atherosclerotic lesions in native superficial femoral artery (sfa) and/or proximal popliteal arteries (ppa).

a prospective, multicenter, single-arm trial evaluating the safety and efficacy of the jetstream atherectomy system in the treatment of symptomatic occlusive atherosclerotic lesions ≤150 mm in length located in the femoropopliteal arteries in subjects with symptoms classified as rutherford categories 2-4.

Eligibility criteria:
inclusion criteria: * chronic, symptomatic lower limb ischemia defined as rutherford categories 2-4 * stenotic, restenotic or occlusive lesion(s) located in the native sfa and/or ppa of which meet all of the following criteria: * calcified lesions with degree of stenosis ≥70% or occlusions * guidewire must cross lesion(s) within the true lumen, without a sub-intimal course * vessel diameter ≥3.0 mm and ≤6.0 mm * total lesion length (or series of lesions) ≤150mm * target lesion located at least 3 cm above the inferior edge of the femur by visual estimate * patent infrapopliteal and popliteal artery exclusion criteria: * target lesion/vessel with in-stent restenosis * target lesion/vessel previously treated with drug-coated balloon \<12 months prior to the procedure * target lesion/vessel previously treated with any stent placement, atherectomy, laser or other debulking devices prior to the procedure * subjects who have undergone surgery or endovascular of the sfa/ppa in the target vessel to treat atherosclerotic disease within 3 months prior to the index procedure * use of drug-coated devices, atherectomy, laser or other debulking devices other than the jetstream system, chronic total occlusion (cto) devices or cutting balloon, angioscore or similar devices in the target limb sfa/ppa during the index procedure * history of major amputation in the target limb * subject has a history of coagulopathy or hypercoagulable bleeding disorder * subject with untreatable hemorrhagic disease or platelet count \ 600,000mm3 as baseline assessment. * concomitant renal failure with a serum creatinine \>2.0 mg/dl * receiving dialysis or immunosuppressant therapy * history of myocardial infarction, or stroke/cerebrovascular accident (cva) within 6 months prior to study enrollment * unstable angina pectoris at the time of the enrollment * septicemia at the time of enrollment * presence of other hemodynamically significant outflow lesions in the target limb requiring a planned surgical intervention or endovascular procedure within 30 days after the index procedure * presence of aneurysm in the target vessel * acute ischemia and/or acute thrombosis of the sfa/ppa prior to the index procedure * perforated vessel as evidenced by extravasation of contrast media prior to the index procedure

Keywords: superficial femoral artery proximal popliteal artery endovascular therapy atherectomy
retrospective study of the health benefits of ultra-violet filtering contact lenses

Conditions: Refractive Errors

Summary: the purpose of this study is to examine the long term effect of ultra-violet filtering contact lenses on macular pigment density (mpod) and accommodative function.


Eligibility criteria:
inclusion criteria: * the subject is an adapted soft contact lens wearer of at least 5 years duration of either an uv filtering contact lens or a non-uv filtering contact lens * the subject must report wearing their contact lenses, on average, for a minimum of 5 days each week. * the subject must have best corrected visual acuity of 6/7.5 or better in each eye. * the subject must appear able and willing to adhere to the instructions set forth in this clinical protocol. * the subject must read and sign the statement of informed consent * the subject must be between 18 and 43 years of age exclusion criteria: * on medication known to affect accommodation * active ocular surface pathology * had eye surgery * significant ocular tissue anomaly * any medical condition that may be prejudicial to the study * diabetes
the clinical trial to evaluate the efficacy and safety of ckd-497

Conditions: Respiratory Infection

Summary: to evaluate the efficacy and safety of ckd-497


Eligibility criteria:
inclusion criteria: 1. 19 ≤ age \< 75 2. subject with acute upper respiratory infection and acute bronchitis infection 3. subject who agreeds to participate in this clinical trial voluntarily exclusion criteria: 1. subject who need antibiotics treatment during the clinical trial 2. subject suffering from severe respiratory diseases such as pneumonia, asthma, chronic closed lung diseases (copd), tuberculosis, bronchial enlargement, malignant tumors in the lungs, and chronic bronchitis during screening 3. subject who cannot participate in a clinical trial based on the pi's judgment

Keywords: acute upper respiratory infection acute bronchitis
clinical evaluations and laboratory studies to study the disease course in patients with cutaneous t-cell lymphoma

Conditions: Lymphoma

Summary: rationale: gathering information about patients with cutaneous t-cell lymphoma over time may help doctors learn more about the disease. purpose: this natural history study is collecting disease-related health information over time from patients with cutaneous t-cell lymphoma.

objectives: primary * follow the disease course of patients with cutaneous t-cell lymphoma. * provide a patient population for study by proteomic and molecular analysis. * develop a mechanism for screening by a tumor board for enrollment of patients in therapeutic clinical trials. secondary * develop a tissue bank for future disease study using specimens from these patients. * provide community outreach by offering a second opinion regarding treatment of this disease in these patients and, in limited cases, provide standard-of-care treatment to these patients. * develop an algorithm for screening and evaluating this disease in these patients. outline: patients undergo disease assessment by physical examination, full-body photographic documentation of skin disease, biopsy, and blood sampling at baseline and then at least annually thereafter. proteomic and molecular methods are used to analyze samples. biopsies may be examined using histologic and immunohistochemical methods. blood may be analyzed by polymerase chain reaction for clonal t-cell gene rearrangements or by flow cytometry. projected accrual: a total of 100 patients will be accrued for this study within 5 years.

Eligibility criteria:
disease characteristics: * diagnosis of 1 of the following: * histologically confirmed stage ia-ivb cutaneous t-cell lymphoma (ctcl) (mycosis fungoides or sézary syndrome) * other histologically and clinically confirmed primary or secondary ctcl * histologically and clinically confirmed pre-ctcl skin condition, including large plaque parapsoriasis and lymphomatoid papulosis * measurable disease by skin lesion assessment or sézary cell count patient characteristics: age * over 18 performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * human t-cell lymphotrophic virus (htlv) i/ii negative * not pregnant * negative pregnancy test prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: stage i cutaneous t-cell non-hodgkin lymphoma stage ii cutaneous t-cell non-hodgkin lymphoma stage iii cutaneous t-cell non-hodgkin lymphoma stage iv cutaneous t-cell non-hodgkin lymphoma stage i mycosis fungoides/sezary syndrome stage ii mycosis fungoides/sezary syndrome stage iii mycosis fungoides/sezary syndrome stage iv mycosis fungoides/sezary syndrome